Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Oral Oncology
|
November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
K J Harrington, E E W Cohen, D Soulières, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial
L Belin, M Kamal, C Mauborgne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A R Abdul Razak, D Soulières, S A Laurie, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2018
Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival
C Dubot, V Bernard, M P Sablin, et al.
British Journal of Cancer
|
May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C Le Tourneau, B Dreno, Y Kirova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F Mosele, B Stefanovska, A Lusque, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
A Moreira, J Masliah-Planchon, C Callens, et al.
Breast (Edinburgh, Scotland)
|
November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
P Gougis, M Carton, C Tchokothe, et al.
ESMO Open
|
May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
C Baldini, E Charton, E Schultz, et al.
ESMO Open
|
August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
E Charton, C Baldini, Y Fayet, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Oral Oncology
|
November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
K J Harrington, E E W Cohen, D Soulières, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial
L Belin, M Kamal, C Mauborgne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A R Abdul Razak, D Soulières, S A Laurie, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2018
Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival
C Dubot, V Bernard, M P Sablin, et al.
British Journal of Cancer
|
May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C Le Tourneau, B Dreno, Y Kirova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F Mosele, B Stefanovska, A Lusque, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
A Moreira, J Masliah-Planchon, C Callens, et al.
Breast (Edinburgh, Scotland)
|
November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
P Gougis, M Carton, C Tchokothe, et al.
ESMO Open
|
May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
C Baldini, E Charton, E Schultz, et al.
ESMO Open
|
August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
E Charton, C Baldini, Y Fayet, et al.
Page
of 6